S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer Recurrent
Interventions: DRUG: S1 plus Docetaxel|DRUG: Capecitabine plus Docetaxel
Sponsor: Chinese Academy of Medical Sciences